Xcout IntelSign inSubscribe

GELSTAT CORP

GSACPharmaceuticalsPalm City, United States

GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers. This is achieved both through direct sales and via independent sales brokerage agreements. The corporation maintains its principal office in Palm City, Florida.

Subscribe to see GELSTAT CORP’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

GELSTAT CORP at a glance

GELSTAT CORP is a pharmaceuticals company headquartered in Palm City, United States. It is publicly listed (GSAC) with a market capitalisation of $185,394. Xcout tracks 12 named people at GELSTAT CORP, including Javier G. Acosta (Chief Executive Officer & Director).

Industry
Pharmaceuticals
Headquarters
Palm City, United States
Market cap
$185,394
Employees
2
Ticker
GSAC

GELSTAT CORP leadership

  • Javier G. AcostaChief Executive Officer & Director
  • Charles F. TarzianChief Marketing Advisor
  • Roger K. CadyChief Medical Advisor
  • Adrian Graham GoldfarbDirector
  • Donald MillerDirector
  • James Bryant LaFlammeDirector

6 more named people on record for GELSTAT CORP, with roles, board committees and tenure — see the full roster →

GELSTAT CORP competitors

A few of GELSTAT CORP's closest competitors — see the full list of competitors and alternatives →

NUTRA PHARMA CORPNPHC · PharmaceuticalsBoca Raton, United States
65% matchPublic

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.

Market cap$715,972
Employees4
NUTRA PHARMA CORP competitors & alternatives →
CV Sciences, Inc.CVSI · PharmaceuticalsSan Diego, United States
64% matchPublic

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

Market cap$2.3M
Employees47
CV Sciences, Inc. competitors & alternatives →
China Pharma Holdings, Inc.CPHI · PharmaceuticalsHaikou, China
64% matchPublic

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.

Market cap$3.8M
Employees224
China Pharma Holdings, Inc. competitors & alternatives →

Get GELSTAT CORP's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

GELSTAT CORP — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on GELSTAT CORP in Xcout Intel

  • 12 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →